What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

RMD Open

Volumn 3, Issue 1, 2017, Pages

  Bouman, Chantal A M ^a   Den Broeder, Alfons A ^a,b   Van Der Maas, Aatke ^a   Van Den Hoogen, Frank H J ^a,b   Landewé, Robert B M ^c   Van Herwaarden, Noortje ^a  

^a Sint Maartenskliniek Nijmegen ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anti TNF; Disease Activity; DMARDs (biologic); Rheumatoid Arthritis; Treatment

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; HUMAN; INCIDENCE; JOINT RADIOGRAPHY; JOINT SWELLING; MAJOR CLINICAL STUDY; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHARP VAN DER HEIJDE SCORE; TREATMENT OUTCOME;

EID: 85015924283     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000327     Document Type: Article

References (13)

1. van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350: h1389.
2. Welsing PM, Landewé RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
3. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
4. Landewé R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
5. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
6. den Broeder AA, van Herwaarden N, van der Maas A, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299.
7. van der Heijde D. How to read radiographs according to the Sharp/ van der Heijde method. J Rheumatol 1999;26:743-5.
8. Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. J Rheumatol 2006;33:501-7.
9. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82.
10. van der Maas A, Lie E, Christensen R, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800-5.
11. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59-67.
12. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
13. Raffeiner B, Botsios C, Ometto F, et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol 2015;33:63-8.